Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin (original) (raw)

Abstract

DaunoXome is a liposome formulation containing daunorubicin (DM). Encapsulation of the drug in liposomes presents the advantage of low-level systemic exposure and better drug penetration into the tumor. We studied the distribution of DM and its 13-dihydro metabolite, daunorubicinol (DMol), in surgical biopsies from different parts of glioblastomas. The study was performed in eight patients with recurrent glioblastoma, all of whom had previously undergone surgery and been treated with radiotherapy and chemotherapy, who received 50 mg of DaunoXome as a 1-h infusion. Surgery was performed at 24 and 48 h after the infusion in seven cases and one case, respectively. Biopsies were divided into three parts: the central area of the tumor, peripheral tumor tissue, and brain-adjacent tumor (BAT) tissue. A complete plasma pharmacokinetics study was conducted in seven cases, with samples being taken for up to 48 h after the end of the infusion. DM and DMol were determined in plasma and tissue by high-performance liquid chromatography with fluorescence detection after solvent extraction. At 24 h, concentrations of DM and DMol in the central part of the tumor ranged between <0.005 and 0.80 μg/g and between 0.005 and 1.58 μg/g, respectively. Concentrations were similar in the peripheral tumor and in BAT tissue. From the data obtained on the patient who underwent surgery at 48 h it appears that DM and DMol remain in tumor tissue for a long time, the concentrations being 0.4 and 2.8 μg/g, respectively. DaunoXome was rapidly cleared from the body, with the plasma levels of DM and DMol determined at 48 h lying in the range of <5–50 and <5–20 ng/ml, respectively. The mean (±SD) half-life and plasmatic clearance of DM were 4.8 ± 1.0 h and 0.2 ± 0.06 l h−1 m−2. In conclusion, DaunoXome achieved and maintained potentially cytotoxic levels of both DM and DMol in glioblastoma for a long time in association with low-level systemic exposure. Further studies are therefore warranted. Although only preliminary and obtained in previously treated patients, these data suggest that DaunoXome merits investigation in CNS tumors.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, I-20157 Milan, Italy Tel.: +39/02/39014470; Fax: +39/02/3546277 E-mail: zucchetti@irfmn.mnegri.it, , , , , , IT
    Massimo Zucchetti, Idria Parisi & Maurizio D'Incalci
  2. Istituto Nazionale Neurologico C. Besta, Via Celoria 11, I-20133 Milan, Italy, , , , , , IT
    Amerigo Boiardi & Antonio Silvani
  3. Nexstar Pharmaceuticals Italia S.r.l., Via G. Frua 16, I-20146 Milan, Italy, , , , , , IT
    Stefano Piccolrovazzi

Authors

  1. Massimo Zucchetti
    You can also search for this author inPubMed Google Scholar
  2. Amerigo Boiardi
    You can also search for this author inPubMed Google Scholar
  3. Antonio Silvani
    You can also search for this author inPubMed Google Scholar
  4. Idria Parisi
    You can also search for this author inPubMed Google Scholar
  5. Stefano Piccolrovazzi
    You can also search for this author inPubMed Google Scholar
  6. Maurizio D'Incalci
    You can also search for this author inPubMed Google Scholar

Additional information

Received: 2 November 1998 / Accepted: 5 January 1999

Rights and permissions

About this article

Cite this article

Zucchetti, M., Boiardi, A., Silvani, A. et al. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.Cancer Chemother Pharmacol 44, 173–176 (1999). https://doi.org/10.1007/s002800050964

Download citation